This San Diego biotech reception is an open, informal networking evening hosted by Crystal Bio Solutions (CBS), Crystal NAX and Crystal Pharmatech on February 24, 2026. It is designed for CMC leaders, analytical development scientists, and biotech R&D teams who want to discuss real development challenges in biologics, small molecules, and nucleic acids.
The purpose is direct, peer-level discussion about development, analytics, and manufacturing strategy.
This event is intended for:
If you are exploring how to de-risk analytical strategy before IND, compare CMC partners, or clarify bioanalytical requirements, this event supports that decision.
Early CMC discussions reduce downstream regulatory and comparability risk. In practice, many development bottlenecks emerge from misalignment between analytical characterization, manufacturing constraints, and regulatory expectations.
Because development decisions made before IND submission influence stability interpretation, impurity control strategy, and clinical comparability, informal technical dialogue can clarify risk early. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consistently emphasize early control strategy definition and lifecycle management in guidance documents.
For teams evaluating development partners, the real question is not only capability but integration across:
Analytical characterization
Bioanalysis and immunogenicity testing
Formulation and process development
Regulatory alignment
This reception creates space to discuss those integration points before formal vendor engagement.
Senior scientific leaders from Crystal Pharmatech and Crystal Bio Solutions will be present. They represent expertise across small molecules, biologics CMC analytics, bioanalysis, nucleic acid development, and formulation strategy.
Discussions may include:
IND-enabling CMC analytical packages
ADC drug-to-antibody ratio (DAR) characterization
Impurity profiling and stability-indicating methods
Bioanalytical assay validation for clinical programs
RNA synthesis and lipid nanoparticle (LNP) development
Conversations are technical and unscripted. There is no slide deck.
The reception supports discussion across three development platforms.
|
Platform |
Typical Development Questions |
Applicable Stage |
|
Small Molecules |
Solid form selection, polymorph control, formulation risk |
Preclinical to clinical |
|
Biologics (CBS) |
CMC analytics, DAR profiling, bioanalysis, immunogenicity |
Pre-IND to Phase III |
|
Nucleic Acids |
RNA synthesis, dsRNA impurities, LNP formulation |
Discovery to early clinical |
These discussions are exploratory. Formal project scoping or regulatory advice requires structured engagement and confidentiality agreements.
Summary
The San Diego Biotech Reception hosted by Crystal Bio Solutions and Crystal Pharmatech on February 24, 2026, is an informal networking evening designed for CMC, analytical, and R&D leaders. It provides a setting to discuss biologics, small molecule, and nucleic acid development challenges, including IND-enabling analytics, bioanalysis, formulation, and manufacturing strategy. The event is free, unscripted, and focused on technical dialogue within the San Diego biotech community.
This event is not a substitute for regulatory consultation. The goal of this meeting is to encourage networking discussions.
Date: February 24, 2026
Time: 5:30 PM to 8:30 PM PST
Location: San Diego, Sorrento Mesa Area, California
Schedule:
5:30 PM Opening remarks
5:45 PM Networking and cocktails
8:15 PM Closing remarks
Attendance is free of charge. This is an open gathering for the San Diego biotech community. Register at the top of the page.
For logistical information, contact:
bd_global@crystalpharmatech.com
Is registration required for the San Diego biotech networking event?
Yes, please register on this page. This is an open reception for biotech and pharma R&D professionals.
Is this event focused on biologics or small molecules?
Both. Crystal Pharmatech supports small molecule development, while Crystal Bio Solutions focuses on biologics CMC analytics and bioanalysis. Nucleic acid programs are supported through Crystal NAX.
Can we discuss IND-enabling CMC strategy?
Yes. Informal discussions about analytical readiness, comparability risk, and CMC control strategy are appropriate. Formal regulatory advice requires structured engagement.
Is this a technical seminar or presentation?
No. There are no formal technical talks. The format is conversational.
Who should attend from a biotech company?
CMC leads, analytical scientists, clinical pharmacology teams, translational leads, and founders evaluating development partners will find the discussion most relevant.
Can we explore potential collaboration?
Yes. The reception is designed to allow early-stage discussion about whether Crystal Bio Solutions or Crystal Pharmatech may be an appropriate CMC or development partner.